VVT Med Inc. VVTM

VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a medical technology company focused on minimally invasive treatments for venous disease, today announced that CHS Ltd., one of Canada's established medical technology organizations, has selected ScleroSafe® as the latest addition to its vascular portfolio and entered into an exclusive commercialization agreement dated September 30, 2026, to support the introduction of the technology in Canada.

VVT Med (VVTM.V) completed the second tranche of its non-brokered private placement offering of unit

VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT"), a leader in minimally invasive, non-thermal and non-tumescent solutions for venous disease, is pleased to announce that, on September 10, 2026, the Company completed the second tranche ("Tranche 2") of its previously announced non-brokered private placement offering (the "Offering").

VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced progress in its entry into the Portuguese market under its Trial Distribution and Evaluation Agreement (the "Agreement") with Dermworks, a Portuguese pharmaceutical and medical device distributor.

VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent solutions for venous disease, today announced proposed debt settlement transactions, together with grants of stock options and restricted share units to directors and employees.

VVT Med Inc. (TSXV: VVTM) ("VVTMed" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent solutions for venous disease, today announced the signing of an exclusive distribution agreement dated June 25, 2026 for the commercialization of the Company's VVT's ScleroSafe® platform in Greece (the "Distribution Agreement") with General Chemical Products S.A. ("GCP"), an established Greek medical technology company with more than four decades of experience supporting hospitals

VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT") is providing an update with respect to its previously announced management cease trade order ("MCTO") issued by the British Columbia Securities Commission (the "BCSC") under National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), as previously disclosed in the news releases of the Company dated April 17, 2026 (the "Default Announcement"), May 1, 2026, May 15, 2026 and May 29, 2026 (collectively, the "MCTO News

Structured Market Entry Includes Initial Purchase Order and Pathway to Five-Year Commercial PartnershipVANCOUVER, BC, June 11, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced its entry into the Dominican Republic market through a Trial Distribution and Evaluation Agreement (the "Agreement") with Antilles Medical ("Antilles"), a local distributor w

Leading Italian Vein Specialist Dr. Luca Palombi and His Team Successfully Treat First Patients in Italy Using the ScleroSafe™ SystemVANCOUVER, BC, May 26, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced that the first group of patients has been treated at with its ScleroSafe™ System in Italy by Dr. Luca Palombi and his team, in collaboration with

Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30VANCOUVER, BC, April 30, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, is pleased to announce the publication of a peer-reviewed clinical study evaluating the short-term efficacy and safety of its ScleroSafe(R) catheter-directed sclerotherapy system. The study, au

Five-Year Agreement Represents Approximately CAD $2.3 Million in Minimum Purchase Commitments | Distributor Joins as Investor in the Company’s Ongoing Private PlacementVANCOUVER, BC, April 27, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a leader in next-generation, minimally invasive, non-thermal, and non-tumescent ("NT-NT") solutions for venous disease, is pleased to announce that it has entered into its largest European distribution agreement to date, a str

VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT"), a leader in minimally invasive, non-thermal and non-tumescent solutions for venous disease, is pleased to announce that, on April 21, 2026, the Company completed the first tranche of its previously announced non-brokered private placement offering for up to gross proceeds of $3,000,000, issuing 4,262,654 units (each, a "Unit") at a price of $0.25 per Unit for gross proceeds of $1,065,663.50 (the "Offering").

VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT"), a leader in minimally invasive, non-thermal and non-tumescent solutions for venous disease, is pleased to announce its intention to complete a non-brokered private placement offering of up to 12,000,000 units (each, a "Unit") at a price of $0.25 per Unit for gross proceeds of up to $3,000,000 (the "Offering").